Efficacy and safety of letermovir for cytomegalovirus prophylaxis in thoracic organ transplantation: a systematic review and meta-analysis Authors: Abdullah Yousef Aldalati, Ayham Mohammad Hussein, Khald Aldalati, Bara M. Hammadeh, Bassel Alrabadi, Ahmad Al-dabagh, Moath Albliwi, Mohammad Abuassi, Badi Rawashdeh Published: 2025 ABSTRACT ObjectiveLetermovir (LTV) is a novel antiviral agent approved for cytomegalovirus (CMV) prophylaxis in high risk allogeneic hematopoietic stem cell transplantation. However, its efficacy and safety in thoracic organ transplant (TOT) recipients remain underexplored. This study systematically evaluates the efficacy and safety of LTV prophylaxis for CMV infection in TOT recipients.MethodsA systematic search of PubMed, Scopus, Web of Science, Embase, and Cochrane Library was conducted up to February 2025. Studies assessing LTV prophylaxis in adult TOT were included. We performed a single-arm meta-analysis using Open Meta Analyst software and a double-arm meta-analysis with Review Manager. Dichotomous outcomes were pooled as event rates using the fixed-effects model.ResultsEleven studies with 380 patients were included. The single-arm meta-analysis showed that LTV prophylaxis was associated with a 3.7% (95% CI: 0.006, 0.069) breakthrough CMV infection rate. The incidence of low-level CMV viremia was 15.8% (95% CI: 0.070, 0.245). The percentage of patients who discontinued LTV due to adverse effects was only 1.7% (95% CI: -0.002, 0.035), while 79.9% (95% CI: 0.610, 0.988) experienced improvement in leukopenia. The double-arm meta-analysis showed no statistically significant difference in breakthrough CMV infection rates between LTV and valganciclovir (VGC) (RR: 0.40; 95% CI: 0.09, 1.68; P = 0.21).ConclusionLTV prophylaxis demonstrates promising efficacy and safety in reducing breakthrough CMV infection, low-level viremia, and adverse events in TOT recipients. Its favorable safety profile, particularly in mitigating leukopenia, highlights its potential as an effective alternative to VGC.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-025-12206-5. Introduction Cytomegalovirus (CMV) is a ubiquitous opportunistic pathogen that significantly impacts transplant recipients, contributing to increased morbidity and mortality [1, 2]. This is particularly true for solid organ transplant recipients, who are susceptible to clinically significant CMV infection, potentially manifesting as CMV syndrome or end-organ disease. High-risk mismatch transplantations, where a CMV seropositive donor organ is transplanted into a CMV seronegative recipient, are associated with an elevated risk of adverse outcomes [1]. To counteract post-transplant CMV infection, many medical institutions practice prophylactic antiviral therapy for high-risk candidates [3]. As of today, current practice in most cases involves administration of indirect viral polymerase inhibitors, namely ganciclovir and valganciclovir [2]. Despite efficacy, use of these drugs can sometimes be hindered through toxic side effects, such as myelosuppression, potentially necessitating dose adjustments, treatment discontinuation, or modifications to immunosuppressive regimens [2]. Letermovir (LTV), a new terminase inhibitor with selective activity towards CMV, gained approval for use in allogeneic hematopoietic stem transplantation in CMV-infected donors in 2017 [4]. LTV is approved for prophylactic use in high risk kidney transplantation at present, but thorough studies proving its efficacy in thoracic organ transplantation have yet to be conducted. LTV can possibly serve as a safer alternative for valganciclovir (VGC) in thoracic organ transplant (TOT) recipients, in part through its reduced myelosuppressive activity. Lung transplant require prolonged courses of CMV prophylaxis compared with other organ transplants, and a lesser level of immunosuppression in this group could possibly contribute towards a reduced rejection rate [5]. Considering the inherent requirement for sufficient immunosuppression to mitigate rejection, compounded by clinical practice guideline recommendations discouraging antiviral prophylaxis withdrawal in a preemptive therapy strategy for TOT recipients [6, 7], prophylactic agents against CMV are of paramount clinical significance. Therefore, in an attempt to undertake a thorough evaluation of approaches for preventing CMV infection in thoracic organ transplantation, a systematic review and meta-analysis were conducted. Methods This systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines [8]. We registered the protocol on the International Prospective Register of Systematic Reviews (PROSPERO) (No. CRD42025645670). Search strategy and eligibility criteria A comprehensive search was conducted across PubMed, Scopus, Embase, Web of Science, and Cochrane library databases from inception up to February 2025. The search strategy was developed using Medical Subject Headings (MeSH) terms and keywords such as letermovir, cytomegalovirus, lung, heart, and transplant. Detailed search strategies for each database are provided in Table S1. Additionally, the reference lists of retrieved articles were reviewed to ensure a comprehensive search. No restrictions were imposed on the language or publication year of the articles. Studies were included if they: [1] used LTV as a primary or secondary prophylactic agent against CMV in [2] adult patients [3] following cardiothoracic organ transplantation. Studies that did not meet these criteria were excluded. Study selection, data extraction, and outcomes Two authors independently screened the titles and abstracts of the studies. Full texts of potentially eligible studies were then obtained for a more detailed assessment. Any disagreements were resolved through consultation with a third author. Then, the same authors independently extracted data using a standardized Excel sheet. Certain data were extracted from the included studies, including the study characteristics, baseline data, efficacy data, and safety data. The outcomes were breakthrough CMV infection (defined as the presence of clinically significant CMV infection), low-level CMV viremia (defined as the present of quantifiable CMV DNAemia without clinically significant disease), discontinuation due to adverse effects, and the improvement in leukopenia status. Risk of bias assessment The risk of bias in the included studies was assessed using the Newcastle-Ottawa Scale (NOS) [9]. This tool evaluates cohort and case-control studies across three domains encompassing eight specific criteria: the selection of study groups, the comparability of these groups, and the ascertainment of the exposure of interest. Studies scoring seven to nine out of a maximum of nine points were classified as high-quality. Those scoring between four and six were considered to be of fair quality, while studies receiving three points or fewer were categorized as low-quality. The Joanna Briggs Institute (JBI) critical appraisal tool was used for one case series study [10]. It assesses key aspects such as the clarity of inclusion criteria, consistency in measuring conditions across cases, appropriateness of statistical analyses, and adequacy of follow-up to capture outcomes. Statistical analysis A single-arm meta-analysis was performed using Open Meta Analyst software (Version 3.13). Dichotomous outcomes were pooled as event and total to calculate the overall event rate with corresponding 95% confidence intervals (CI). Additionally, a double-arm meta-analysis was conducted to compare the incidence of breakthrough CMV infection between the LTV group and the control group. This analysis was performed using Review Manager (Version 5.4), with pooled risk ratios (RR) calculated using the Mantel-Haenszel method. A fixed-effects model was applied when heterogeneity was below 50%, while a random-effects model was applied when heterogeneity was 50% or higher. Heterogeneity across studies was evaluated using the Cochrane Q chi-square test and the I² statistic. The heterogeneity were considered low if I² < 50% and high if I² >50%. Results Study selection and characteristics The initial search identified 1721 papers, of which 1049 remained after the removal of duplicates. Following the screening process, 23 papers were selected for full-text review. Of these, 12 were excluded for not meeting the inclusion criteria. Finally, 11 studies [11–21] were eligible and included in the analysis (Fig. 1). Fig. 1Forest plot of study selection flow chart Forest plot of study selection flow chart The studies included in this study were published between 2019 and 2024 and included a total of 380 patients receiving LTV prophylaxis. The mean age of the patients ranged from 46 to 65 years. Nine studies were conducted in the USA [11, 13–16, 18–21], one in France [12], and one in Japan [17]. The main characteristics of the included studies are reported in Table 1. Table 1Characteristics of the included studies and letermovir dosage regimenStudy IDCountryStudy designTransplant typeHigh risk patients ((D+/R-)(n)Primary/Secondary (n)No. of patients (n)Gender (n)Agemean (SD)Letermovir doseFrequency of administrationAryal et al. 2019USARetrospective cohortTOT62/68M = 4F = 5-480 mgDailySingha et al. 2021USARetrospective cohortLT159/817M = 10F = 760 (8)480 mgDailySaullo et al. 2022USARetrospective cohortTOT2125/1641M = 25F = 1651.3 (12)480 mg720 mg for patients at high riskDailyGolob et al. 2022USARetrospective cohortHT11-17M = 8F = 956 (12)480 mg720 mg for patients at high riskDailyKleiboeker et al. 2024 aUSARetrospective case-controlLT829/029M = 13F = 1663 (13)480 mgDailyKleiboeker et al. 2024 bUSARetrospective cohortLT829/029M = 13F = 1659 (12)480 mgDailyHirama et al. 2024JapanRetrospective cohortLT33/47M = 5F = 2-480 mgDailySaltiel et al. 2024FranceRetrospective cohortHT52/810M = 5F = 546 (22)480 mgDailyMezochow et al. 2024USARetrospective cohortLT3488/088M = 55F = 3357 (15)480 mgDailyMartinez et al. 2024USARetrospective, matched cohortHT39124/0124M = 77F = 4765 (8)480 mg900 mg for patients at high riskDailyTran et al. 2024USARetrospective chart reviewLT49/110M = 6F = 356 (21)480 mgDailyThe age is represented in years. SD: standard deviation, M: male, F: female, TOT: Thoracic Organ Transplantation, LT: lung transplantation, HT: heart transplantation Table 1Characteristics of the included studies and letermovir dosage regimenStudy IDCountryStudy designTransplant typeHigh risk patients ((D+/R-)(n)Primary/Secondary (n)No. of patients (n)Gender (n)Agemean (SD)Letermovir doseFrequency of administrationAryal et al. 2019USARetrospective cohortTOT62/68M = 4F = 5-480 mgDailySingha et al. 2021USARetrospective cohortLT159/817M = 10F = 760 (8)480 mgDailySaullo et al. 2022USARetrospective cohortTOT2125/1641M = 25F = 1651.3 (12)480 mg720 mg for patients at high riskDailyGolob et al. 2022USARetrospective cohortHT11-17M = 8F = 956 (12)480 mg720 mg for patients at high riskDailyKleiboeker et al. 2024 aUSARetrospective case-controlLT829/029M = 13F = 1663 (13)480 mgDailyKleiboeker et al. 2024 bUSARetrospective cohortLT829/029M = 13F = 1659 (12)480 mgDailyHirama et al. 2024JapanRetrospective cohortLT33/47M = 5F = 2-480 mgDailySaltiel et al. 2024FranceRetrospective cohortHT52/810M = 5F = 546 (22)480 mgDailyMezochow et al. 2024USARetrospective cohortLT3488/088M = 55F = 3357 (15)480 mgDailyMartinez et al. 2024USARetrospective, matched cohortHT39124/0124M = 77F = 4765 (8)480 mg900 mg for patients at high riskDailyTran et al. 2024USARetrospective chart reviewLT49/110M = 6F = 356 (21)480 mgDailyThe age is represented in years. SD: standard deviation, M: male, F: female, TOT: Thoracic Organ Transplantation, LT: lung transplantation, HT: heart transplantation Characteristics of the included studies and letermovir dosage regimen M = 4 F = 5 M = 10 F = 7 M = 25 F = 16 480 mg 720 mg for patients at high risk M = 8 F = 9 480 mg 720 mg for patients at high risk M = 13 F = 16 M = 13 F = 16 M = 5 F = 2 M = 5 F = 5 M = 55 F = 33 M = 77 F = 47 480 mg 900 mg for patients at high risk M = 6 F = 3 The age is represented in years. SD: standard deviation, M: male, F: female, TOT: Thoracic Organ Transplantation, LT: lung transplantation, HT: heart transplantation Breakthrough CMV infection Breakthrough CMV infection was reported in ten studies [11–15, 17–21] with 331 patients. The single arm meta-analysis showed that the breakthrough CMV infection rate was 3.7% (95% CI 0.006, 0.069) for patients on LTV prophylaxis. Low heterogeneity was observed among the studies (I2 = 50%, P = 0.034) (Fig. 2). Fig. 2Forest plot of breakthrough CMV infection rate Forest plot of breakthrough CMV infection rate Two studies [14, 15] compared the breakthrough CMV infection event between the LTV group and the valganciclovir group. Although a lower rate of breakthrough CMV infection was observed in the LTV group compared to the valganciclovir group, the difference was not statistically significant (RR = 0.40, 95% CI: 0.09, 1.68, P = 0.21). Low heterogeneity was observed among the studies (I2 = 0%, P = 0.56) (Fig. 3). Fig. 3Forest plot comparing the incidence of breakthrough CMV infection between the LTV group and the control group Forest plot comparing the incidence of breakthrough CMV infection between the LTV group and the control group Low-level CMV viremia Seven studies [12, 13, 17–21] with 161 patients reported CMV viremia events. The single arm meta-analysis showed that 15.8% (95% CI: 0.070, 0.245) of patients on LTV prophylaxis developed low-level CMV viremia, with high heterogeneity observed among the included studies (I² = 55%, P = 0.038) (Fig. 4). Fig. 4Forest plot of low-level CMV viremia rate Forest plot of low-level CMV viremia rate Adverse events Discontinuation of the LTV due to adverse effects was reported in nine studies [11–14, 17–21] with 302 patients. The analysis results indicated that the LTV discontinuation rate was 1.7% (95% CI -0.002, 0.035). Low heterogeneity was observed among the included studies (I2 = 15%, P = 0.309) (Fig. 5). Fig. 5Forest plot of LTV Discontinuation due to adverse effects Forest plot of LTV Discontinuation due to adverse effects Adverse events associated with LTV were generally minor and infrequent. Martinez et al. [14] documented three adverse events, including an episode of hypertension with headache and leukopenia. Saullo et al. [21] reported five adverse events, consisting of two cases of myelosuppression, two cases of fatigue, and one case of nausea. Aryal et al. [19] reported two adverse events, including one case of fatigue and one case of edema. Mezochow et al. [20] reported a single adverse event of headache. Improvement in leukopenia status Four studies [11, 12, 16, 20] with 116 patients reported the improvement in leukopenia status. The analysis showed that 79.9% (95% CI 0.610, 0.988) of patients experienced an improvement in their leukopenia status. High heterogeneity was observed among the included studies (I2 = 89%, P = 0.001) (Fig. 6). Kleiboeker et al. [15] reported that patients on valganciclovir experienced significantly more leukopenia (p = 0.008) and neutropenia (p = 0.048). In addition, Saullo et al. [21] found that from initiation to cessation of LTV prophylaxis, the median white blood cell count increased from 3.1 × 10^9/L to 5.0 × 10^9/L, indicating an improvement in WBC levels during LTV prophylaxis. Fig. 6Forest plot of improvement in leukopenia status rate Forest plot of improvement in leukopenia status rate Risk of bias We performed a quality assessment on all included studies to evaluate their inherent risk of bias. None of the studies were excluded from the analysis due to a known risk of bias that could affect the results. Based on the assessment using the NOS tool, eight studies were of good quality [14–21], while two were rated as fair quality [11, 12]. Additionally, one study was evaluated using the JBI tool, and determined to be of high quality [13]. The detailed quality assessment is shown in Table S2, S3, and S4. Discussion The use of LTV for CMV prophylaxis in TOT recipients represents a promising advancement in post-transplant care. This study provides a comprehensive evaluation of the efficacy, safety, and potential advantages of LTV over conventional antiviral drugs. The meta-analysis results demonstrated that LTV prophylaxis in TOT recipients resulted in a low breakthrough CMV infection rate (3.7%) and low-level viremia (15.8%), with minimal discontinuation (1.7%). Additionally, 79.9% of patients showed improved leukopenia, highlighting LTV’s efficacy and safety in this high-risk population. Current guidelines recommend the use of ganciclovir and VGC, as the primary agents for CMV prophylaxis in TOT recipients, despite their notable risk of adverse effects [2]. Both drugs have demonstrated efficacy in preventing CMV infection and disease [22]. Ganciclovir, in particular, is associated with significant myelosuppressive effects, predominantly neutropenia and leukopenia, which affects the majority of patients [23]. Similarly, VGC is linked to myelosuppression and gastrointestinal adverse events [24]. Given their nephrotoxic potential, both agents necessitate close monitoring and dosage adjustments in patients with renal dysfunction [25]. LTV was recently approved for CMV prophylaxis in high risk adult and pediatric patients undergoing allogeneic hematopoietic stem cell transplantation by the FDA [4, 26]. While LTV is approved for use in high risk kidney transplant recipients, it is not currently approved for TOT or other solid organ transplant recipients, as available data remain limited to a few studies. A randomized phase III clinical trial involving 601 high-risk kidney transplant recipients evaluated the efficacy and safety of LTV in comparison to VGC. The findings demonstrated that LTV was non-inferior to VGC in preventing CMV disease through week 52 [27]. In addition, a study by Winstead et al. investigated the use of LTV in solid organ transplant recipients [28]. The study concluded that patients who switched from VGC to LTV did not demonstrate an increased incidence of CMV breakthrough compared to a historical, matched cohort of patients maintained on VGC. These findings suggest that LTV may represent a promising alternative for CMV prophylaxis in the solid organ transplant population. The analysis results indicated that the breakthrough CMV infection rate was 3.7% when LTV was used. In addition, only 15.8% of patients on LTV prophylaxis experienced low-level CMV viremia. In a randomized clinical trial involving 372 CMV D+/R- recipients of liver, kidney, pancreas, and heart transplants, the rate of CMV disease was similar between patients who received oral ganciclovir and those who received VGC prophylaxis, with rates of 17.2% for VGC and 18.4% for ganciclovir at 12 months [22]. Beam et al. reported a 10.3% rate of breakthrough CMV infection among lung transplant recipients who received VGC prophylaxis [29]. Interestingly, LTV demonstrated a lower rate of breakthrough CMV infection, as reported in our analysis, suggesting its superior efficacy compared to ganciclovir and VGC. This emphasizes the potential utility of LTV in TOT recipients. However, these findings should be interpreted with caution, as the studies were conducted on diverse populations, and large-scale randomized trials are necessary to confirm these results and support LTV approval. The major concern with antiviral agents used for CMV prophylaxis is their associated adverse effects. Ganciclovir and VGC are well known for causing myelosuppression, which increases the risk of infections and bleeding [30, 31]. In our analysis, LTV demonstrated a high level of tolerability, with a discontinuation rate of just 1.7%. Notably, none of the studies included in this analysis reported severe adverse events associated with LTV prophylaxis. While minor adverse events, such as headache and fatigue, were observed, these were infrequent and did not lead to treatment discontinuation in most cases. This favorable safety profile highlights the potential of LTV as a safer and effective alternative for CMV prophylaxis in transplant recipients. Most of the included studies utilized LTV following the cessation of VGC due to severe leukopenia. The analysis revealed that 79.9% of patients experienced an improvement in leukopenia after transitioning from VGC to LTV. The myelosuppressive effects of VGC resolved soon after discontinuation of the drug and initiation of LTV. Notably, this approach not only improved leukopenia without requiring additional supportive measures but also eliminated the need for further modifications to mycophenolate therapy [30]. The dosage regimen for LTV was consistent across most of the included studies, with a standard dose of 480 mg administered to the majority of patients. In certain cases, higher doses of 720 mg or 900 mg were given to patients at high risk for CMV infection. When cyclosporine was co-administered, the LTV dose was reduced by 50% due to cyclosporine’s inhibition of cytochrome P450 3A4, an enzyme involved in LTV metabolism [32]. To the best of our knowledge, this is the first comprehensive review and analysis summarizing the role of LTV prophylaxis in CMV-related outcomes among TOT recipients. This systematic review highlights real-world clinical experiences, although it has certain limitations. The overall sample size of the included studies was relatively small, because of the off-label use of LTV in TOT recipients. Furthermore, the follow-up durations in most studies were generally short, limiting the ability to assess long-term outcomes. Additionally, the majority of studies included in this meta-analysis were retrospective observational studies or nonrandomized designs, which could introduce some bias. A key limitation is that most studies did not report outcomes separately for primary vs. secondary LTV prophylaxis, limiting subgroup analysis. To establish more robust evidence, large-scale randomized controlled trials with control groups or direct comparisons with other antiviral agents in pediatric populations are warranted. Such studies are essential to draw more definitive conclusions regarding the efficacy and safety of LTV in this context. Conclusion LTV prophylaxis demonstrates promising efficacy and safety in reducing breakthrough CMV infection, low-level viremia, and adverse events in TOT recipients. Its favorable safety profile, particularly in mitigating leukopenia, highlights its potential as an effective alternative to VGC. LTV has consistently proven its efficacy and safety across different clinical settings, supporting its broader adoption in thoracic organ transplantation. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1